Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly

This page shows the latest Eli Lilly news and features for those working in and with pharma, biotech and healthcare.

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Advanced pancreatic cancer is notoriously hard to treat, and Eli Lilly’s pegilodecakin has joined the list of drugs unable to improve survival compared to standard chemotherapy. ... The pegylated formulation of interleukin-10 was the main asset in

Latest news

More from news
Approximately 91 fully matching, plus 584 partially matching documents found.

Latest Intelligence

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    Digital detection. One such promising study comes from Eli Lilly, in partnership with Apple and Evidation Health. ... According to Divakar Ramakrishnan, Lilly’s chief digital officer, the findings from this study “could inform subsequent research

  • The fight for affordable insulin The fight for affordable insulin

    The world’s three biggest insulin manufacturers are Novo Nordisk, Sanofi and Eli Lilly. ... Lilly’s authorised generic. One company, Eli Lilly, has responded to the pleas for more affordable insulins, and launched a half price ‘authorised

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Since 2012, AC Immune has partnered tau assets with Roche’s Genentech, Johnson &Johnson and Eli Lilly. ... Sosei Heptares’ work on M1 falls into the latter category. Eli Lilly took an M1 agonist, xanomeline, into phase 3 in the 1990s and emerged with

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    EPAD combines knowledge and expertise from 39 European partner organisations across multiple sectors, including most of the big pharma companies involved in Alzheimer’s research (including Amgen, Janssen and Lilly, among ... Last month, Johnson

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Developed in partnership with Eli Lilly, it has already presented positive phase 3 results, with more expected in the first half of 2019, with filings expected shortly afterwards.

More from intelligence
Approximately 4 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 30 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics